Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MANE with free AI briefings, catalyst countdowns, and dilution alerts.

MANE · Veradermics, Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$798.4M Cash on Hand
128mo Cash Runway
Follow MANE by email Get an email when MANE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MANE, unsubscribe in one click. Privacy

📣 What MANE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
VDPHL01 Androgenetic Alopecia Phase 2/3 · NCT06724614 Active not recruiting
VDPHL01 BID Androgenetic Alopecia (AGA) Phase 3 · NCT07146022 Active not recruiting
VDPHL01 QD Androgenetic Alopecia (AGA) Phase 3 · NCT07146022 Active not recruiting
VDMN-21 Patch High Dose Verruca Vulgaris Phase 2 · NCT05799157 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MANE holds $798.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $18.7M/quarter from operations, an estimated runway of 128 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MANE files for a raise →

👥 Who Owns MANE

Insiders 12.1% Institutions (266 holders) 87.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
SUVRETTA CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 4,172,121 9.89% 2026-05-01
FMR LLC Institution (13G, 5%+) 3,193,181 7.57% 2026-06-30
JPMORGAN CHASE & CO. Institution (13G, 5%+) 2,374,502 5.63% 2026-09-30
John W Childs
Director · +51,525 options
Insider 1,907,889 4.52% 2026-08-12
Longitude Capital Partners V, LLC
10% owner
Insider 1,803,474 4.27% 2026-11-11
Patrick G Enright
Director · +45,131 options
Includes shares also reported by Longitude Capital Partners V, LLC, counted once
Insider 1,803,474 4.27% 2026-11-11
MONTANOVA CAPITAL, LLC
Director
Insider 612,033 1.45% 2026-08-19
Vlad Coric
Director · +51,525 options
Insider 449,337 1.06% 2026-02-03
Reid Alexander Waldman
Chief Executive Officer, Director · +556,399 options
Insider 170,824 0.40% 2026-08-17
Seven Fleet Capital Management LP
10% owner
Insider 80,000 0.19% 2026-05-01
Timothy August Durso
Chief Technical Officer · +213,352 options
Insider 78,142 0.19% 2026-08-17
David Hollander
Chief R&D Officer · +19,300 options
Insider 9,650 0.02% 2026-09-01

Share count 42,195,472 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MANE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MANE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.